EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Bacteriophage therapy beyond antibiotics: emerging innovations for infectious and non-infectious diseases

Biyi Zhang, Xutong Shu, Abdullah Ibna Masud, Joyoshrie Karmakar, Jie Fan, Ishatur Nime, Mrityunjoy Acharjee, Fan Pan, Md Sharifull Islam

Frontiers in Cellular and Infection Microbiology · 08.07.2026 · 16

DOI: 10.3389/fcimb.2026.1879718 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 08.07.2026. Verfasst von Biyi Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology (SUAT), No. 1 Gongchang Road, Guangming District, Shenzhen, China. Hauptthemen laut MEDLINE: Phage Therapy, Bacteriophages, Bacterial Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The advancement of synthetic biology and the rise of antimicrobial resistance have led to the development of bacteriophage therapy for more than antibacterial applications. This review focuses on applications to multidrug-resistant infections, biofilm diseases, cancer research, veterinary medicine and animal production. Recent research suggests phages can be used in combination with antibiotics to enhance treatment of large multidrug resistant pathogens such as Pseudomonas aeruginosa , Acinetobacter baumannii and Klebsiella pneumoniae . This could also help to restore antibiotic sensitivity by making bacteria change resistance related structures or mechanisms. Despite this, there are several challenges for the use of phage therapy prior to its widespread clinical application, including phage resistance, difference in patient response, unknown pharmacokinetic parameters, immune issues, and unclear regulatory guidelines. Additionally, in some cases, phages could also play a role in horizontal gene transfer, raising further safety concerns. Beyond antimicrobial therapy, phage display platforms derived from M13, T7 and λ phages have enabled the identification of tumor-targeting peptides, the development of immunomodulatory constructs, and targeted delivery of therapeutic molecules. Over 100 clinical cases and 44 registered trials support the generally favorable safety profile of personalized phage therapy, and highlight the need for better treatment standardization, controlled clinical evaluation, and better regulatory processes. Additionally, engineered phages expressing biofilm degrading enzymes represent promising tools for disrupting matrix-embedded bacterial communities associated with chronic infections and medical devices. In summary, CRISPR-based engineering and genome refactoring highlight the potential of phage-based therapeutics as complements to conventional antimicrobial therapy, although their broader use depends on overcoming biological, clinical, and regulatory challenges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phage TherapyBacteriophagesBacterial InfectionsHumansAnimalsAnti-Bacterial AgentsBiofilmsDrug Resistance, Multiple, BacterialNeoplasms

Stichwörter der Autor:innen

antimicrobial resistancebacteriophage therapybiofilm eradicationpersonalized medicinephage antibiotic synergy

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Faculty of Pharmaceutical Sciences, Shenzhen University of Advanced Technology (SUAT), No. 1 Gongchang Road, Guangming District, Shenzhen, China.
  • Center for Cancer Immunology, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences (CAS), 1068 Xueyuan Avenue, Shenzhen, China.
  • Department of Microbiology, Stamford University Bangladesh, Dhaka, Bangladesh.
  • College of Clinical Medicine, The First Affiliated Hospital, Henan University of Science and Technology, Luoyang, China.
  • Key Laboratory of Environment Correlative Dietology, College of Food Science and Technology, Huazhong Agricultural University, Wuhan, Hubei, China.

Zitieren

APA

Zhang, B., Shu, X., Masud, A. I., Karmakar, J., Fan, J., Nime, I., Acharjee, M., Pan, F., & Islam, M. S. (2026). Bacteriophage therapy beyond antibiotics: emerging innovations for infectious and non-infectious diseases. Frontiers in Cellular and Infection Microbiology, 16. https://doi.org/10.3389/fcimb.2026.1879718

Vancouver

Zhang B, Shu X, Masud AI, Karmakar J, Fan J, Nime I, et al. Bacteriophage therapy beyond antibiotics: emerging innovations for infectious and non-infectious diseases. Frontiers in Cellular and Infection Microbiology. 2026;16. doi:10.3389/fcimb.2026.1879718

BibTeX
@article{Zhang2026,
  author = {Zhang, Biyi and Shu, Xutong and Masud, Abdullah Ibna and Karmakar, Joyoshrie and Fan, Jie and Nime, Ishatur and Acharjee, Mrityunjoy and Pan, Fan and Islam, Md Sharifull},
  title = {Bacteriophage therapy beyond antibiotics: emerging innovations for infectious and non-infectious diseases},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fcimb.2026.1879718}
}
Kostenlos starten →